MedTrace Logo

Hemlibra

Drug

Also known as: Hemlibra

Drug Profile

Hemlibra (emicizumab-kxwh) is a bispecific antibody prophylactic treatment for hemophilia A in newborns, children, and adults, including those with or without factor VIII inhibitors. It is given subcutaneously with flexible weekly, biweekly, or four-weekly maintenance schedules after loading. Initial U.S. approval was in 2017.

Drug Class
Bispecific factor IXa- and factor X-directed antibody
Approval Status
FDA approved (initial U.S. approval 2017; revised July 2025)
Brand Names
  • HEMLIBRA
Indications
  • \Routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A (congenital factor VIII deficiency) in adult and pediatric patients ages newborn and older, with or without factor VIII inhibitors\

Related News